Q-omics provides the consensus-scored TRBV5-3 profile across patient tissues and cancer cell-line models. TRBV5-3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TRBV5-3 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRBV5-3 RNA expression shows 10,640 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight CESC, KIRC, and PDAC as cancer lineages where TRBV5-3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV5-3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV5-3 survival associations across molecular data types. TRBV5-3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV5-3 RNA expression–survival associations across cancer types. High TRBV5-3 expression shows unfavorable associations in CESC, ACC and BLCA, but favorable associations in ESCA, SKCM and HNSC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TRBV5-3 RNA expression.
This table summarizes TRBV5-3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV5-3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV5-3 shows higher tumor expression in KIRC, UCEC, STAD and PRAD. The KIRC box plot shows higher TRBV5-3 RNA expression in tumor versus normal tissue (log2 FC = +0.061, t-test p = .004).
This table shows molecular features associated with TRBV5-3 in patient tissues and cancer cell lines. In patient samples, TRBV5-3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
